EV/EBITDA for AstraZeneca (AZN)

AstraZeneca (AZN) EV/EBITDA ratio is 15.5× as of June 5, 2026. The 5-year average is 20.1×. The sector median currently stands at 15.0×. The current ratio is at the 11th percentile of its own 10-year history.

AstraZeneca (AZN) historical EV/EBITDA ratio has ranged from a low of 3.6× (2011) to a high of 56.3× (2004) in the available daily series.

The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.